Alvotech's stock moved higher in premarket trading, with shares rising 12% after the company announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application (BLA) for AVT16. The candidate is described by the company as an interchangeable biosimilar to Entyvio, the reference biologic used in treating inflammatory bowel diseases.
In a company statement, Alvotech said that, if the FDA ultimately approves AVT16 as interchangeable, pharmacists could substitute the product for Entyvio without additional action from the prescribing physician. That prospect for pharmacy-level substitution is a central feature of an interchangeable designation and is highlighted by the company as a potential pathway to expanded patient access.
The FDA's acceptance of the BLA initiates a formal regulatory review process. For Alvotech, an Iceland-based biopharmaceutical company, this represents a regulatory milestone on its effort to bring a biosimilar version of Entyvio to market. The company framed the acceptance as a key step toward potentially offering an interchangeable alternative to the reference product.
The market reaction - a double-digit premarket uptick in Alvotech shares - reflects investor attention to regulatory progress in biosimilars, where an interchangeable finding can materially affect distribution dynamics at the point of dispensing. The announcement does not by itself indicate an outcome of the review process; it signals that the FDA has deemed the submission complete enough to be placed under formal consideration.
For stakeholders across the pharmaceutical supply chain, an interchangeable approval would change how pharmacies manage substitutions for Entyvio, though any real-world impact will depend on the ultimate regulatory decision. The company statement underscores substitution at the pharmacy counter as the principal commercial distinction tied to the interchangeable designation.
As Alvotech proceeds through the FDA review, market participants and healthcare sector observers will monitor subsequent regulatory milestones and any timelines the agency provides for its evaluation.